Alnylam Pharmaceuticals | ALNY - Trade Debtors

Stock Price
328.14
Daily Change
-3.10 -0.94%
Monthly
-22.33%
Yearly
18.81%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $964.77M in Trade Debtors for its fiscal quarter ending in September of 2025.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 139.44M 19.75M Sep/2025
Agios Pharmaceuticals USD 5.03M 43K Sep/2025
Alnylam Pharmaceuticals USD 964.77M 397.66M Sep/2025
Amgen USD 8.49B 211M Sep/2025
Arrowhead Research USD 218.87M 212.05M Dec/2025
BioMarin Pharmaceutical USD 790.27M 65.59M Sep/2025
Incyte USD 895.89M 53M Sep/2025
Ionis Pharmaceuticals USD 24.61M 27.97M Sep/2025
Moderna USD 1.05B 589M Sep/2025
Neurocrine Biosciences USD 728M 132.3M Sep/2025
Novartis USD 8.98B 192M Sep/2025
PTC Therapeutics USD 203.07M 6.94M Sep/2025
Regeneron Pharmaceuticals USD 5.74B 54M Dec/2025
Sanofi EUR 397M 186.13M Dec/2025
Sarepta Therapeutics USD 395.74M 213.86M Sep/2025
Takeda JPY 757.92B 55.68B Dec/2025
Tectonic Therapeutic USD 0 270K Dec/2023
Ultragenyx Pharmaceutical USD 112.54M 11.92M Sep/2025
Vertex Pharmaceuticals USD 1.95B 52.9M Sep/2025
Xencor USD 21.8M 25.75M Sep/2025